Key points are not available for this paper at this time.
In a large cohort with extended follow-up, selpercatinib continued to demonstrate durable and robust responses, including intracranial activity, in previously treated and treatment-naive patients with RET fusion-positive NSCLC.
Drilon et al. (2022) studied this question.